Close
ACHEMA MIDDLE EAST 2026

Cell & Gene Therapies: FDA Regulatory Implications For 2024

The fact is that most in the biotech industry know that cell and gene therapies- CGT are regulated across the U.S. as biological products...

Clinical Research Ecosystem Making Utmost Gene Therapy Use?

It is a well-established fact that gene therapy research happens to be booming. Since the U.S. Food and Drug Administration- FDA issued its first...

US Okays Biosecurity Bill Against Chinese Bio Company Deals

In March 2024, one of the biosecurity laws restricting transactions with Chinese bio companies happened to pass the U.S. Congress, and now the global...

Fresh Biologics Clinical Manufacturing CDMO Service Trends

In the ever-changing pharma and biologics sector, the Biologics Clinical Manufacturing CDMO Service market has gone on to emerge as quite a prominent player...

CDMOs Using Specialized Solutions To Meet Cold Chain Needs

It is worth noting that the Cell and gene therapies- CGTs have gone on to show immense promise when it comes to treating diverse...

The After-Effects of A Poor Laboratory Inventory Management

Inventory management happens to be simultaneously the most essential and, at the same time, the most disliked task that laboratorians carry out on a...

Tomorrow Has Lots In Store With Digital Pharma Laboratories

Pharmaceutical labs happen to work with data. Immense data which needs to be stored, assessed, shared and also retrieved. Data which happens to be...

Subscribe Our Newsletter

White Papers

The Future of Digital Health

The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...